Trial Profile

A Phase II, Dose and Frequency Finding Study of MOD-4023 in Growth Hormone Deficient Adults (GHDA)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Somatrogon (Primary)
Indications Somatotropin deficiency
Focus Adverse reactions; Therapeutic Use
Sponsors OPKO Health; PROLOR Biotech

Most Recent Events

23 Feb 2017 Results published in the European Journal of Endocrinology
04 Apr 2016 Results assessing IGF-1 from this and other trial (see profile 259010) presented at The 98th Annual Meeting of the Endocrine Society
04 Apr 2016 Results of a pharmacokinetic and pharmacodynamic modelling presented at The 98th Annual Meeting of the Endocrine Society

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com